<DOC>
	<DOCNO>NCT00509483</DOCNO>
	<brief_summary>Background : Preadministration recombinant human thyrotropin ( rhTSH ) increase amount homogeneity thyroid radioiodine uptake , use adjuvant augment efficiency 131I therapy allow multinodular goitre ( MNG ) volume reduction . Objective : The investigator aim assess low-dose rhTSH-aided fixed-activity radioiodine therapy outcome MNG patient . Design : This long-term ( 36 month ) observational study . Methods : The investigator measure 24 h thyroid radioiodine uptake ( RAIU ) 1.4 ÂµCi ( 0.5 MBq ) 131-iodine baseline 24 h intramuscular injection 0.1 mg rhTSH 42 patient ( age 42-80 year ) subsequently receive 30 mCi 131-iodine 24 h identical rhTSH injection . Urinary iodine measure baseline 3 month follow low iodine diet . TSH , free thyroxine ( FT4 ) , T3 ( T3 ) thyroglobulin ( TG ) measure baseline , 24 h , 48 h , 72 h , 168 h , one month , 3 , 6 , 9 , 12 , 18 , 24 36 month therapy . Thyroid volume assess computer tomography baseline every 6 month thereafter .</brief_summary>
	<brief_title>Three-Year Follow-up Radioiodine Therapy Goitre</brief_title>
	<detailed_description />
	<mesh_term>Goiter</mesh_term>
	<criteria>Patients multinodular goitre Aversion form treatment Previous radioiodine therapy Being unable complete prolong followup ; Having serious cardiovascular disorder .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>multinodular</keyword>
	<keyword>goitre</keyword>
	<keyword>recombinant human TSH</keyword>
</DOC>